Stay updated on Risankizumab Maintenance in Psoriasis Clinical Trial
Sign up to get notified when there's something new on the Risankizumab Maintenance in Psoriasis Clinical Trial page.

Latest updates to the Risankizumab Maintenance in Psoriasis Clinical Trial page
- Check2 days agoChange DetectedThe page's revision label in the footer was updated from v3.6.0 to v3.6.3, indicating a newer build/version of the page.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedRecruitment status was updated with a new note that the study is no longer looking for participants. Additional navigation and labeling updates were added, including How to Read a Study Record, Common Questions, How to Join a Study, and Intervention/Treatment, along with the Revision: v3.6.0 label.SummaryDifference0.1%

- Check23 days agoChange DetectedRevision: v3.5.5 has been applied, replacing the previous Revision: v3.5.4. This represents a minor software update to the interface and does not modify any study data or displayed content.SummaryDifference0.0%

- Check44 days agoChange DetectedRevision label updated from v3.5.3 to v3.5.4 in the Study Documents, indicating a new version of documents is available. This reflects updated Protocol and Statistical Analysis Plan materials associated with the AbbVie study.SummaryDifference0.0%

- Check66 days agoChange DetectedThe website’s ClinicalTrials.gov footer was updated from revision v3.5.2 to v3.5.3, indicating a platform release/version update.SummaryDifference0.0%

- Check73 days agoChange DetectedAdded 'State of Vienna' as the location designation and updated Vienna addresses to 'Vienna, State of Vienna, Austria, 1030' and '1090', replacing the previous 'Vienna' entries. Also updated the page revision from v3.5.0 to v3.5.2.SummaryDifference0.1%

Stay in the know with updates to Risankizumab Maintenance in Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Risankizumab Maintenance in Psoriasis Clinical Trial page.